Open AccessToxoplasmosis - An update
Author(s) -
Veena Mittal,
Rattan Ichhpujani
Publication year - 2011
Publication title -
tropical parasitology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.418
H-Index - 11
eISSN - 2229-7758
pISSN - 2229-5070
DOI - 10.4103/2229-5070.72109
Subject(s) - toxoplasmosis , folinic acid , disease , toxoplasma gondii , sulfadiazine , transmission (telecommunications) , pyrimethamine , medicine , immunology , transplacental , population , malaria , serology , pediatrics , pregnancy , virology , biology , fetus , antibiotics , environmental health , pathology , chloroquine , microbiology and biotechnology , placenta , colorectal cancer , cancer , antibody , engineering , genetics , electrical engineering
Toxplasmosis is an important zoonotic disease caused by protozoan parasite Toxoplasma gondii. The disease affects one-third of the total world population. Transmission of the disease is mainly by ingestion of food or water contaminated with oocysts. Congenital toxoplasmosis occurs from the transplacental passage of the parasite from mother to fetus. In most adults it does not cause serious illness, but it can cause blindness and mental retardation in congenitally infected children, and it is a devastating disease in immunocompromised individuals. Diagnosis of toxoplasmosis can be established by the direct detection of the parasite or by serological methods. The most commonly used and effective therapeutic regimen is the combination of pyrimethamine with sulfadiazine and folinic acid. This article provides an overview and update on transmission, diagnosis, management, and prevention of toxoplasmosis.